

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/651,136	08/28/2003	Sandor Sipka	22740-2	8175	
24256 DINSMORE &	7590 03/01/200° SHOHL, LLP	7	EXAMINER		
1900 CHEMED CENTER 255 EAST FIFTH STREET CINCINNATI, OH 45202			ROONEY, NORA MAUREEN		
			ART UNIT	PAPER NUMBER	
			1644		
			MAIL DATE	DELIVERY MODE	
			03/01/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	10/651,136	SIPKA ET AL.				
Before the Filing of an Appeal Brief	Examiner	Art Unit				
	Nora M. Rooney	1644				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 1/23/2007 & 2/8/2007 FAILS TO PLACE TI						
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:						
a) The period for reply expires 3 months from the mailing date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date	on which the petition under 37 CFR 1.1	36(a) and the appropria	te extension fee			
have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL						
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS						
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because						
(a) They raise new issues that would require further co	nsideration and/or search (see NO					
 (b) ☐ They raise the issue of new matter (see NOTE below) (c) ☐ They are not deemed to place the application in be 	•	ducing or simplifying	the issues for			
appeal; and/or	tter form for appeal by materially re	ducing or simplifying	uie issues ioi			
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: (See 37 CFR 1.116 and 41.33(a)).						
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).						
5. Applicant's reply has overcome the following rejection(s):						
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: <u>1-5,10,13 and 17-19</u> . Claim(s) withdrawn from consideration:						
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 						
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to a showing a good and sufficient reasons why it is necessar	overcome all rejections under appe	al and/or appellant fai	ils to provide a			
10. ☑ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER						
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application in	n condition for allowa	nce because:			
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).						
13. Other:						

Continuation of 11. does NOT place the application in condition for allowance because:

Claims 1-5, 10, 13 and 17-19 stand rejected under 35 U.S.C. 103(a) for teh same reasons as previsouly set forth in the action mailed on 10/23/2006. Applicant has raised a new issue in the amendment after final and 37 C.F.R. 1.132 declarations submitted on 1/23/2007 and 02/08/2007.

Applicant sets forth argument in a declaration filed under C.F. R. 1.132 on 02/08/2007 that is not sufficient to overcome the rejection. On pages 2-3 of the declaration, applicant argues that the Bertok et al. prior art reference (IDS filed on 10/04/2004) should not be used since it uses LPS to induce a nonspecific resistance for the pretreatment of shocks, radiation disease and infections which does not teach, suggest or recognize the use of radiation detoxified LPS to stimulate a specific response to inhibit allergic disease.

Applicant's arguments set forth in the declarations filed on 02/08/2007 and 01/23/2007 have been fully considered, but are not found pursuasive. Lin et al. (PTO-892, Reference U) shows that the specific immune response to an airway antigen is dependent upon the innate nonspecific immune response and controls whether a Th1 or Th2 response in generated in mice. In particular, the reference teaches that LPS may be used to alter airway function and that the interaction of LPS with lung cells further influences the specific immune response to develop a Th1 or Th2 response in Balb/cJ and C57BL/6J mice. (In particular, abstract; page 502, paragraph spanning left and right columns; page 505, paragraph spanning left and right columns). Therefore, one of ordinary skill in the art at the time of invention would have known that the nonspecific reistance induced by radiation-detoxified LPS could be applied to inhibit allergic disease because it had been shown that the specific immune response to airway allergen was determined by the nonspecific immune response to LPS.

MAHER M. HADDAD PRIMARY EXAMINER

Maker M Hodde